SCHEMBL6803385

SCHEMBL6803385

CCOC(=O)CC(C)(C)Cc1ccc(O)c(OC)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 1/20 0.51
ALDH1A1 P00352 2/20 0.50
TSHR P16473 2/20 0.50
GAA P10253 1/20 0.50
NFKB1 P19838 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
MAOB P27338 1/20 0.49
KDM4E B2RXH2 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2C8 P10632 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2B6 P20813 2/20 0.47
CYP2C19 P33261 2/20 0.47
ALOX5 P09917 2/20 0.47
OR51E2 Q9H255 1/20 0.47
TRPV1 Q8NER1 6/20 0.46
CYP2E1 P05181 1/20 0.46
HTR1A P08908 1/20 0.46
LTA4H P09960 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6800487 0.83 HPGD (0.38) ALDH1A1GAATDP1KDM4ECYP1A2
SCHEMBL358270 0.81 HSD17B2 (0.54) HSD17B2ALDH1A1TSHRGAANFKB1
SCHEMBL2002022 0.80 ALDH1A1 (0.67) HSD17B2ALDH1A1TSHRGAANFKB1
SCHEMBL30038050 0.80 ALDH1A1 (0.67) HSD17B2ALDH1A1TSHRGAANFKB1
SCHEMBL6809494 0.79 KMT2A (0.48) ALDH1A1GAATDP1KDM4E
SCHEMBL6809716 0.79 ESR1 (0.47) TSHR
Dihydroferulic Acid Ethyl Ester SCHEMBL356300 0.78 ALOX5 (0.67) HSD17B2ALDH1A1TSHRGAANFKB1
SCHEMBL27886589 0.77 HSD17B2 (0.55) HSD17B2ALDH1A1TSHRGAANFKB1
SCHEMBL27728471 0.76 HSD17B2 (0.51) HSD17B2ALDH1A1TSHRGAANFKB1
SCHEMBL8409515 0.76 ALDH1A1 (0.52) HSD17B2ALDH1A1TSHRGAANFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043994-A1 Gem-substituted alpha v beta 3 antagonists PHARMACIA CORPORATION 2004-03-04 US disclosed
EP-1313705-A1 GEM-SUBSTITUTED ALPHA V BETA 3 INTEGRIN ANTAGONISTS Pharmacia Corporation (US) 2003-05-28 EP disclosed
US-6531494-B1 Gem-substituted αvβ3 antagonists PHARMACIA CORPORATION 2003-03-11 US disclosed
WO-2002018340-A1 GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS PHARMACIA CORPORATION (US) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043994-A1 Gem-substituted alpha v beta 3 antagonists CACNG5, ITGAV, ITGA5 HSD17B2 4266/4885ALDH1A1 2319/4885TSHR 2272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.